share_log

Oppenheimer Reiterates Outperform on Vor Biopharma, Maintains $8 Price Target

Benzinga ·  Mar 21 14:42

Oppenheimer analyst Matthew Biegler reiterates Vor Biopharma (NASDAQ:VOR) with a Outperform and maintains $8 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 374

Recommended

Write a comment